Home/Pipeline/RIG-101

RIG-101

Asthma

Pre-clinicalActive

Key Facts

Indication

Asthma

Phase

Pre-clinical

Status

Active

Company

RIGImmune

About RIGImmune

RIGImmune is a private, preclinical-stage biotech founded in 2020 by Yale professors Anna Marie Pyle and Akiko Iwasaki. The company has built an integrated platform combining Stem Loop RNA (SLR) therapeutics, which selectively activate the RIG-I pathway, with the NEED™ (Nano-Emulsion Enhanced Delivery) platform for direct, non-LNP inhalation delivery. Its pipeline targets high-unmet-need respiratory conditions like asthma and cystic fibrosis, positioning it to address a significant market opportunity if its localized delivery approach proves successful in the clinic.

View full company profile

Therapeutic Areas

Asthma Cystic Fibrosis Respiratory Diseases

Other Asthma Drugs

Drug	Company	Phase	Status
Technegas® for Asthma	Cyclomedica	Phase 2	Active
Asthma Candidate	Teva	Phase 3	Active
Montelukast Amorphous Form	Morepen Laboratories	Phase-2	Active
Chitinase Inhibitor	Lead Discovery Siena	Discovery	Active
SKB378	Klus Pharma	Phase 1	Active
Asthma Clinical Trials	American Health Research	Not Disclosed	Active
Advanced Asthma Products	Polpharma	Not Disclosed	Active
Solrikitug	Uniquity Bio	Phase 2	Active
Asthma Trial	Science 37	Phase 3	Completed/Highlighted
CAL-4	Calyxha Biotechnologies	Preclinical	Active
Digital Biomarker for Asthma	electronRx	Early Development	Active
Flutiform	KYORIN Pharmaceutical	Marketed	Active